MUC1 and acute respiratory distress syndrome: A screen by Kost-Alimova et al.<sup>1</sup> suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).